TSXV:CVM.H - Post by User
Comment by
ICT1111on Mar 10, 2020 4:56pm
77 Views
Post# 30790323
RE:RE:RE:Who Cares?
RE:RE:RE:Who Cares?Don't know what world you live in........
1/ You have a short memory, only 203 tests from approval? Don't forget the sh*t loads of objections and questions the FDA had. 2/ 'All it takes in the US is some hype' ..... maybe so, but not in a company that was subject to a CTO and then got delisted .... and a little investgation will reveal that Global chewed their way through C$25+million ..... what is not to like? Everything!. 3/ Why would anyone invest in either company when they are locked together? Medical own the worldwide commercial rights, Global own the IP; they are mutually reliant, they have to come together or they die together ..... and those within Global will see both companies in the gutter before they do a commercially viable deal; the most extraordinary self interest that i have ever seen. 4/ Why would anyone put new money into this when the first 4 or 5 $million of that new money will be used to pay old debt?
There are several more significant reasons why this 'restructuring' will not work but i will keep my powder dry on that for the time being.
Finally, 'Hack's replecement is very qualified' ..... i can't find any significant history on her ..... unlike Kanter, Hellman and D'orta ...... i have heard talk of the potential of what they are doing to be 'the most significant device since the invention of the stent' yet the team in charge made a complete mess of it whilst flushing millions .... rushing the application, private planes taking Bakema around the US, changing the specification of the device mid way through the FDA process, $150,000 on renovations to a house not owned by the company etc, etc, etc.......
and finally finally, within 2 years one, two or three of the current/ex directors of Medical will go to prison for a variety of Fiduciary crimes against the shareholders and the creditors ..... this is a public company and the dirctors have a responsibility to behave in the best interest of the investors.